{"id":"NCT03047005","sponsor":"Yale University","briefTitle":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy","officialTitle":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-08-28","primaryCompletion":"2021-12-16","completion":"2022-12-16","firstPosted":"2017-02-08","resultsPosted":"2023-05-06","lastUpdate":"2024-02-02"},"enrollment":68,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Binge-Eating Disorder","Obesity"],"interventions":[{"type":"DRUG","name":"NB medication (Naltrexone Bupropion combination)","otherNames":["Contrave"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"NB medication","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test the effectiveness and relative efficacy of naltrexone/bupropion medication as a maintenance therapy for the treatment of binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in superior maintenance and longer-term outcomes compared with placebo.","primaryOutcome":{"measure":"Binge Eating Frequency (Continuous)","timeFrame":"Post-treatment (4 months)","effectByArm":[{"arm":"NB Medication","deltaMin":0.86,"sd":2.15},{"arm":"Placebo","deltaMin":3.25,"sd":7.06}],"pValues":[{"comp":"OG000 vs OG001","p":".07"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Insomnia","Constipation","Dry Mouth","Headache","Nausea"]}}